关注
Helen Rizos
Helen Rizos
在 mq.edu.au 的电子邮件经过验证
标题
引用次数
引用次数
年份
Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1/anti-CTLA-4 combined therapy
TN Gide, C Quek, AM Menzies, AT Tasker, P Shang, J Holst, J Madore, ...
Cancer cell 35 (2), 238-255. e6, 2019
6622019
BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact
H Rizos, AM Menzies, GM Pupo, MS Carlino, C Fung, J Hyman, LE Haydu, ...
Clinical cancer research 20 (7), 1965-1977, 2014
5712014
Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma
GV Long, C Fung, AM Menzies, GM Pupo, MS Carlino, J Hyman, ...
Nature communications 5 (1), 5694, 2014
3912014
Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma
ES Gray, H Rizos, AL Reid, SC Boyd, MR Pereira, J Lo, V Tembe, ...
Oncotarget 6 (39), 42008, 2015
3472015
Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms
DB Johnson, AM Menzies, L Zimmer, Z Eroglu, F Ye, S Zhao, H Rizos, ...
European journal of cancer 51 (18), 2792-2799, 2015
3412015
Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma
JH Lee, GV Long, S Boyd, S Lo, AM Menzies, V Tembe, A Guminski, ...
Annals of Oncology 28 (5), 1130-1136, 2017
3152017
Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1–based immunotherapy
SY Lim, JH Lee, TN Gide, AM Menzies, A Guminski, MS Carlino, EJ Breen, ...
Clinical Cancer Research 25 (5), 1557-1563, 2019
3022019
Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis
TJ Parmenter, M Kleinschmidt, KM Kinross, ST Bond, J Li, MR Kaadige, ...
Cancer discovery 4 (4), 423-433, 2014
2922014
Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti–programmed cell death 1 antibodies
JH Lee, GV Long, AM Menzies, S Lo, A Guminski, K Whitbourne, ...
JAMA oncology 4 (5), 717-721, 2018
2852018
Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-κB
K Gowrishankar, D Gunatilake, SJ Gallagher, J Tiffen, H Rizos, P Hersey
PloS one 10 (4), e0123410, 2015
2462015
A melanoma-associated germline mutation in exon 1β inactivates p14ARF
H Rizos, S Puig, C Badenas, J Malvehy, AP Darmanian, L Jiménez, ...
Oncogene 20 (39), 5543-5547, 2001
2272001
Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
SJ Welsh, H Rizos, RA Scolyer, GV Long
European journal of cancer 62, 76-85, 2016
2242016
WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors
JN Anastas, RM Kulikauskas, T Tamir, H Rizos, GV Long, EM Von Euw, ...
The Journal of clinical investigation 124 (7), 2877-2890, 2014
2172014
Transcriptional downregulation of MHC class I and melanoma de-differentiation in resistance to PD-1 inhibition
JH Lee, E Shklovskaya, SY Lim, MS Carlino, AM Menzies, A Stewart, ...
Nature communications 11 (1), 1897, 2020
2082020
Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium
RN Amaria, AM Menzies, EM Burton, RA Scolyer, MT Tetzlaff, ...
The Lancet Oncology 20 (7), e378-e389, 2019
2022019
Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma
YNV Gopal, H Rizos, G Chen, W Deng, DT Frederick, ZA Cooper, ...
Cancer research 74 (23), 7037-7047, 2014
1932014
Differentiation of cucumber mosaic virus isolates using the polymerase chain reaction
H Rizos, LV Gunn, RD Pares, MR Gillings
Journal of General Virology 73 (8), 2099-2103, 1992
1591992
Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial
GV Long, RPM Saw, S Lo, OE Nieweg, KF Shannon, M Gonzalez, ...
The Lancet Oncology 20 (7), 961-971, 2019
1572019
Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma
SY Lim, AM Menzies, H Rizos
Cancer 123 (S11), 2118-2129, 2017
1542017
Mutations in the INK4a/ARF melanoma susceptibility locus functionally impair p14ARF
H Rizos, AP Darmanian, EA Holland, GJ Mann, RF Kefford
Journal of Biological Chemistry 276 (44), 41424-41434, 2001
1492001
系统目前无法执行此操作,请稍后再试。
文章 1–20